Cargando…
PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
Current standard immunomodulatory therapy with interferons (IFNs) for relapsing–remitting multiple sclerosis (MS) exhibits proven, but limited, efficacy and increased side effects due to the need of frequent application of the drug. Therefore, there is a need for more effective and tolerable drugs....
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686537/ https://www.ncbi.nlm.nih.gov/pubmed/23807836 http://dx.doi.org/10.2147/BTT.S29948 |